Blue Cross partners with Onduo to provide diabetes management wearable

Cara Livernois | | Health Exec | Economics

Blue Cross and Blue Shield has announced a partnership with Onduo, an Alphabet-backed wearable device for the monitoring of glucose levels in diabetic patients.

A year after the launch of Onduo by Alphabet, with the aim to produce technologies for the improved self-management of diabetes, the partnership with Blue Cross will provide individuals the ability to improve health outcomes with the technology.

“We’re working on finding those innovations in the market that will move the needle and improve our (health plan) members' lives,” said Maureen Sullivan, Blue Cross and Blue Shield Association senior vice president and chief strategy officer.

Read the full story below:

Blue Cross Plans Partner With Alphabet Venture To Manage Diabetes

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Walgreens $10B private equity buyout financed by 83% debt
Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice
VA planning 83,000 layoffs as part of restructuring

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.